Opin vísindi

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants

Show simple item record

dc.contributor.author NCD Risk Factor Collaboration (NCD-RisC)
dc.date.accessioned 2023-02-16T01:04:32Z
dc.date.available 2023-02-16T01:04:32Z
dc.date.issued 2021-09-11
dc.identifier.citation NCD Risk Factor Collaboration (NCD-RisC) 2021 , ' Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants ' , The Lancet , vol. 398 , no. 10304 , pp. 957-980 . https://doi.org/10.1016/S0140-6736(21)01330-1
dc.identifier.issn 0140-6736
dc.identifier.other 70303798
dc.identifier.other 1ffdff63-ffd3-40ea-aea7-abf4a88c3675
dc.identifier.other 85114679906
dc.identifier.other 34450083
dc.identifier.uri https://hdl.handle.net/20.500.11815/3988
dc.description Funding Information: This study was funded by WHO. BZ is supported by a fellowship from the Abdul Latif Jameel Institute for Disease and Emergency Analytics, funded by a donation from Community Jameel, at Imperial College London, London, UK. ME is supported by the British Heart Foundation (Centre of Research Excellence grant RE/18/4/34215). Funding Information: RC reports grants from the Ministry of Health of the Czech Republic; and personal fees from Herbacos Recordati, Amegen, and Krka, outside the submitted work. GD reports consulting fees from Vital Strategies; and an honorarium from the American College of Cardiology, outside the submitted work. ME reports a charitable grant from the AstraZeneca Young Health Programme; and personal fees from Prudential, outside the submitted work. CJP reports holding stocks in Pfizer, outside the submitted work. JS reports ownership in companies providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lily, Boehringer Ingelheim, Bayer, Pfizer, and AstraZeneca, outside the submitted work. MW reports personal fees from Amgen, Kyowa Kirin and Freeline, outside the submitted work. All other authors declare no competing interests. Publisher Copyright: © 2021 World Health Organization
dc.description.abstract Background: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods: We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings: The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Funding: WHO.
dc.format.extent 24
dc.format.extent 7516376
dc.format.extent 957-980
dc.language.iso en
dc.relation.ispartofseries The Lancet; 398(10304)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Medicine (all)
dc.title Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1016/S0140-6736(21)01330-1
dc.relation.url http://www.scopus.com/inward/record.url?scp=85114679906&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine
dc.contributor.department Department of Engineering

Files in this item

This item appears in the following Collection(s)

Show simple item record